Home » Stocks » Pulmonx

Pulmonx Corporation (LUNG)

Stock Price: $42.24 USD -0.82 (-1.90%)
Updated Oct 23, 2020 4:00 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 1.43B
Revenue (ttm) 31.74M
Net Income (ttm) -28.08M
Shares Out 32.47M
EPS (ttm) -0.86
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Oct 23, 2020
Last Price $42.24
Previous Close $43.06
Change ($) -0.82
Change (%) -1.90%
Day's Open 42.89
Day's Range 40.47 - 43.92
Day's Volume 332,780
52-Week Range 37.64 - 52.00

More Stats

Market Cap 1.43B
Enterprise Value 1.44B
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 32.47M
Float 7.13M
EPS (basic) n/a
EPS (diluted) -0.86
FCF / Share n/a
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short n/a
Short Ratio n/a
Short % of Float n/a
Beta n/a
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 45.15
PB Ratio 42.80
Revenue 31.74M
Operating Income n/a
Net Income -28.08M
Free Cash Flow n/a
Net Cash -10.35M
Net Cash / Share -0.31
Gross Margin 70.61%
Operating Margin n/a
Profit Margin -88.46%
FCF Margin n/a
ROA n/a
ROE n/a
ROIC n/a
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (0)

Buy 0
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: n/a

Price Target

*No analysts have provided price targets for this stock.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Revenue Growth62.94%-
Gross Profit22.4112.29
Operating Income-17.84-15.05
Net Income-20.70-18.48
Shares Outstanding1.781.67
Earnings Per Share-11.66-11.03
Operating Cash Flow-20.77-18.39
Capital Expenditures-0.72-0.30
Free Cash Flow-21.49-18.69
Cash & Equivalents28.354.12
Total Debt21.8133.61
Net Cash / Debt6.53-29.48
Book Value-187-167
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Pulmonx Corporation
Country United States
Employees 202
CEO Glendon E. French

Stock Information

Ticker Symbol LUNG
Stock Exchange NASDAQ
Sector Health Technology
Industry Medical Specialties
Unique Identifier NASDAQ: LUNG
IPO Date October 1, 2020


Pulmonx Corporation, a medical technology company, designs, develops, manufactures, and markets minimally invasive medical devices for the diagnosis and treatment of chronic obstructive pulmonary diseases. It offers Zephyr Endobronchial Valve, a solution for the treatment of bronchoscopic in adult patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console with flow and pressure sensors that are used to assess the presence of collateral ventilation. The company also provides StratX Lung Analysis Platform, a cloud-based quantitative computed tomography analysis service that offers information emphysema destruction, fissure completeness, and lobar volume to help identify target lobes for the treatment with Zephyr Valves. It serves emphysema patients in Europe, the Middle East, Africa, the Asia-Pacific, the United States, and internationally. Pulmonx Corporation was formerly known as Pulmonx and changed its name to Pulmonx Corporation in December 2013. The company was incorporated in 1995 and is headquartered in Redwood City, California.